A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2007
This article has no abstract
Epistemonikos ID: 570d5a89f14648f5a4d70ba077afce073e5893be
First added on: Jan 21, 2025